The Q&A on the conference call (as has been common lately) focused around 214. The company did not disclose much new information. They did say there have been no reports of Vascular Leak Syndrome (I did a little searching and saw that is a common IL2 side effect http://www.ncbi.nlm.nih.gov/pubmed/9403331 ). They reiterated the plan to start combination studies later this year and to provide some top-line data as a single agent (though they expect some patients to be on drug). One analyst really tried to push to at least see where they were but no luck. Said even with initial dose would expect to see some activity but no mention of what cohort (they are planning 6) or how many patients are enrolled.
In other news... 181 (their pain drug) completed enrollment and top-line data still expected for Q1 '17. Human abuse trial to start Q4 with data in Q2 '17. IND for NKTR-358 (autoimmune diseases) planned for Q1 '17. Phase 3 readouts from Bayer programs Cipro inhale and Amikacin inhale still 2H '16/Q1 '17. Ophthotech’s Fovista Q4 '16 readout.
Nektar is up again around ~4% so in 2 months and a week or so the stock is up ~50% on really no news (The Q2 report/call was basically uneventful).
While I can't be 100% certain I think its extremely likely related to NKTR-214. The study is open label and should be well into an efficacious dose. The combination portion should be starting relatively soon too. Since its open label some people should obviously know. The other thing of note is I've noticed Howard Robin likes to keep a sizeable amount of cash (above the level of their debt) and with the appreciation he's had ample opportunity to raise cash. I'd imagine 214 if the data is good is unlikely to pursued alone because of the broad application the question is how early would it be partnered or would the company just be acquired? If AZ had confidence in Movantik would seem like the ideal fit.
News 
Market Data 
Discover 
